Azitra (AZTR) Net Income towards Common Stockholders (2022 - 2026)

Azitra (AZTR) posted Net Income towards Common Stockholders of -$3.9 million for Q1 2026, down 75.83% on a QoQ basis from -$2.2 million in Q4 2025, and down 27.99% year-over-year from -$5.5 million in Q1 2025.

Azitra (AZTR) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends

Azitra's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$3.9 million for Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 27.99% year-over-year to -$3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.8 million (down 29.78% YoY) and the FY2025 annual result came in at -$11.0 million, down 22.17% from the prior year.
  • Net Income towards Common Stockholders was -$3.9 million for Q1 2026 at Azitra, down from -$2.2 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$1.0 million in Q3 2024 and bottomed at -$5.1 million in Q2 2023.
  • A 5-year average of -$2.9 million and a median of -$2.8 million in 2025 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 48.22% — and 2025, when it slumped 173.85%.
  • Azitra's Net Income towards Common Stockholders stood at -$4.7 million in 2022, then jumped by 48.22% to -$2.5 million in 2023, then increased by 2.47% to -$2.4 million in 2024, then rose by 6.67% to -$2.2 million in 2025, then tumbled by 75.83% to -$3.9 million in 2026.
  • Business Quant data shows AZTR's Net Income towards Common Stockholders at -$3.9 million in Q1 2026, -$2.2 million in Q4 2025, and -$2.8 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Nanobiotix 1,785.82 Bn 1,785.76 Bn - -
2 Akari Therapeutics 979.03 Bn 979.03 Bn - -14.46 Mn
3 BeOne Medicines 472.98 Bn 468.19 Bn 1.35 Bn 227.36 Mn
4 Vertex Pharmaceuticals 123.73 Bn 116.48 Bn 2.59 Bn 1.03 Bn
5 Regeneron Pharmaceuticals 71.59 Bn 62.84 Bn 3.31 Bn 727.20 Mn
6 Belite Bio 62.00 Bn 62.00 Bn - -0.68
7 Argenx Se 54.67 Bn 49.49 Bn 1.41 Bn 472.00 Mn
8 Alnylam Pharmaceuticals 37.96 Bn 34.95 Bn 959.66 Mn 205.99 Mn
9 Revolution Medicines 36.08 Bn 36.08 Bn - -453.82 Mn
10 Azitra 2.07 Mn 2.07 Mn - -3.93 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -3.93 Mn
Dec 31, 2025 -2.23 Mn
Sep 30, 2025 -2.76 Mn
Jun 30, 2025 -2.89 Mn
Mar 31, 2025 -3.07 Mn
Dec 31, 2024 -2.39 Mn
Sep 30, 2024 -1.01 Mn
Jun 30, 2024 -2.63 Mn
Mar 31, 2024 -2.93 Mn
Dec 31, 2023 -2.45 Mn
Sep 30, 2023 -1.94 Mn
Jun 30, 2023 -5.07 Mn
Mar 31, 2023 -3.17 Mn
Dec 31, 2022 -4.74 Mn
Sep 30, 2022 -3.11 Mn
Jun 30, 2022 -2.58 Mn